Rezolute, Inc. (NASDAQ:RZLT) Stock Has Consensus Target Price of $11.22

Shares of Rezolute, Inc. (NASDAQ:RZLT) have been given an average rating of “Moderate Buy” by the fourteen brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $11.22.

A number of analysts recently weighed in on the stock. Citizens Jmp increased their price target on shares of Rezolute from $11.00 to $15.00 and gave the company a “market outperform” rating in a research report on Tuesday, October 6th. Wall Street Zen cut shares of Rezolute from a “hold” rating to a “sell” rating in a report on Tuesday, June 30th. Citigroup restated an “outperform” rating on shares of Rezolute in a report on Tuesday, October 6th. Cantor Fitzgerald raised shares of Rezolute from a “neutral” rating to an “overweight” rating in a research note on Monday, October 5th. Finally, HC Wainwright upped their target price on shares of Rezolute from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, September 25th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RZLT. Sequoia Financial Advisors LLC acquired a new stake in Rezolute during the 2nd quarter worth approximately $75,000. WINTON GROUP Ltd bought a new position in Rezolute in the second quarter valued at approximately $88,000. Integrated Wealth Concepts LLC acquired a new position in shares of Rezolute in the second quarter valued at approximately $143,000. Wellington Management Group LLP acquired a new position in shares of Rezolute in the second quarter valued at approximately $276,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Rezolute in the second quarter valued at approximately $267,000. 82.97% of the stock is owned by institutional investors and hedge funds.

Rezolute Price Performance

RZLT stock opened at $4.23 on Thursday. The stock’s fifty day simple moving average is $4.44 and its two-hundred day simple moving average is $4.17. Rezolute has a 1-year low of $1.07 and a 1-year high of $11.46.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings data on Thursday, September 24th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). On average, equities research analysts forecast that Rezolute will post -0.63 earnings per share for the current fiscal year.

Rezolute Company Profile

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. The company’s research is centered on conditions involving abnormal insulin signaling and glucose regulation, including rare disorders and complications associated with diabetes.

Rezolute’s lead investigational product is RZ358, a human monoclonal antibody designed to reduce the effects of excessive insulin activity. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin and causes potentially dangerous episodes of low blood sugar.